

Influenza B virus Nucleoprotein antibody [8C8]

Cat. No. GTX00707

Host	Mouse
Clonality	Monoclonal
Isotype	lgG1
Applications	ICC/IF, IP, ELISA
Reactivity	Influenza B virus

References (1) Package 100 μg

Applications

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
ICC/IF	1:100
IP	1:100
ELISA	Assay dependent
Not tested in other applications	

Product Note

This antibody reacts with NP of all Influenza B viruses so far tested (113 clinical strains), including Yamagata lineage strains; Mie/1/1993, JohanesBurg/5/1999, Florida/4/2006 and Victoria lineage strains; Lee/1940, Gif/21/1973, Shangdong/7/1997, Malasia/2506/2004, Massachustts/2/2012. No cross reactivity with influenza A viruses.

Properties	
Form	Liquid
Buffer	Filter-sterilized PBS, 50% Glycerol
Preservative	No preservative
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
Concentration	1 mg/ml (Please refer to the vial label for the specific concentration.)
Immunogen	Human Influenza B Virus strain Nagasaki/1/87, one of the strains of B/Victoria group.
Purification	Purified IgG From tissue culture supernatant
Conjugation	Unconjugated



For full product information, images and publications, please visit our website.

Date 2025 / 06 / 15 Page 1 of 2




For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

Note

Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.

DATA IMAGES



GTX00707 ICC/IF Image

ICC/IF analysis of MDCK cells infected with Influenza B virus using GTX00707 Influenza B virus Nucleoprotein antibody [8C8]

Upper: The cells infected with an Influenza B virus vaccine strain, Malaysia/2506/2004 as a representative of Victoria group.

Lower: The cells infected with an Influenza B virus vaccine strain, Florida/4/2006 as Yamagata group.

Fixation: 4% PFA in PBS

Permeabilization: 0.1% Triton X-100 in PBS



For full product information, images and publications, please visit our <u>website</u>.

Date 2025 / 06 / 15 Page 2 of 2